It is estimated that over 7 million people are living with Alzheimer's Disease in Europe, and there is increasing concern about the ability to combat the disease with Europe's ageing population. In this series of articles, Euractiv will explore the state …
Over the past ten years, treatments for multiple myeloma have progressed significantly, allowing French patients to live longer. However, much progress remains to be made, particularly in access to innovative drugs.
Scientific advances in the detection and treatment of Alzheimer’s disease offer cause for optimism, but health systems will need to evolve to deliver meaningful change for those affected.
Spinal muscular atrophy (SMA) is a rare, progressive, neuromuscular disease which affects one in 11,000 births. It is the most common neurodegenerative disease in childhood. Before any treatment was available, a diagnosis of SMA meant either early death or a lifetime of progressive disability. There are now a number of disease-modifying treatment options for SMA approved in Europe, with more treatments under development.
